Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio

Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%. Media Contact: Reiterates full year 2024 guidance Forward-Looking Statements Chemaxon develops leading software products for chemical structure drawing, prop ...